Abbott & Novo Nordisk India Join Forces to Launch New Semaglutide Brand “Extensior” and Expand Diabetes Care Access
Diabetes care in India is set for a major expansion as Abbott and Novo Nordisk India have announced a strategic partnership to introduce a second brand of the GLP‑1 diabetes treatment semaglutide marketed globally as Ozempic under the name Extensior.
| Abbott and Novo Nordisk India collaborate to launch Extensior, a second semaglutide brand to expand diabetes care access across India. |
Under this collaboration, Abbott will leverage its extensive distribution network across India to commercialise Extensior and reach a broader range of patients beyond the urban centres where Novo Nordisk has traditionally focused.
What Is Extensior and Why It Matters
Extensior is a once‑weekly semaglutide injection approved as an adjunct to diet and exercise to manage blood glucose levels in adults living with type 2 diabetes. Semaglutide a GLP‑1 receptor agonist has shown significant benefits in lowering HbA1c, aiding weight control, and reducing risks of heart and kidney complications among people with type 2 diabetes.
While Ozempic is already available in India, the launch of Extensior will help improve access particularly in regions where availability has been limited by combining Novo Nordisk’s clinical expertise with Abbott’s supply and reach.
What This Means for Patients
India carries one of the largest diabetes burdens in the world with over 100 million people affected, and that number is expected to rise sharply in the coming decades. Extensior’s expanded distribution may make cutting‑edge diabetes care more accessible, especially for patients outside major cities who struggle to find advanced therapies.
Both companies have highlighted that this partnership reflects a shared commitment to tackling the diabetes epidemic in India. Extensior will be offered in a convenient weekly injection device with a range of dose strengths, and is expected to be available soon.
Comments
Post a Comment